Health · 1 sources covering this

STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics

Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/21e915d9264bf4c7e60d9a855111c445b2f8aaa0"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics"></iframe>

STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics

How 1 sources are covering this

STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics

More from Health

Affordable Care Act insurers want more premium increases as enrollment sags

Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study says

STAT+: Europe will accelerate its review of RevMed’s drug

STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics

More from Health

Affordable Care Act insurers want more premium increases as enrollment sags

Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study says

STAT+: Europe will accelerate its review of RevMed&#8217;s drug

STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more

Reader

Trust & legal

Across the network

STAT+: Europe will accelerate its review of RevMed’s drug